BioCorRx Reports 3,627% Revenue Growth in Q1 2025 Amid Continued Losses and Liquidity Concerns

BioCorRx Inc. (OTCMKTS: BICX) has recently released its quarterly financial results for the period ending March 31, 2025. Here’s a concise overview of the key points from their income statement and operational insights:

• Revenue Growth: BioCorRx reported a net revenue of $134,899 for Q1 2025, a significant increase from $3,620 in Q1 2024, reflecting a staggering growth of 3,627%.
• Operating Expenses: Total operating expenses rose to $1,072,845, up from $972,312 year-over-year. Major contributions to this increase were from rising accounting and legal fees.
• Net Loss: The net loss for the quarter was $851,764, improved from a loss of $1,237,463 in the prior year's quarter.
• Grant Income Surge: The company recognized $413,979 in grant income, compared to $112,963 in Q1 2024, due to successful funding from the National Institutes of Health (NIH).
• Debt Settlement Costs: The firm incurred a loss on debt settlement amounting to $132,514 due to amendments on promissory notes during the quarter.
• Cash Position: As of the end of March 2025, the company had cash reserves of $24,142 and experienced net cash used in operating activities totaling $689,623.
• Working Capital Deficit: The working capital deficit was $12,878,438, raising concerns about liquidity moving forward.
• Asset Purchase Agreement: On March 4, 2025, BioCorRx entered into an agreement to acquire assets related to Lucemyra, resulting in the company taking on additional liabilities.
• Stock Issuances: The company issued a total of 1,770,452 shares in connection with conversions of promissory notes, reflecting their strategy to manage debts via equity.
• Impact of Legal Issues: The company settled a litigation case that required a payment of $418,000 to Pellecome, which was a significant challenge for the quarter.

While BioCorRx has demonstrated remarkable growth in revenues, managing an increasing loss margins and addressing its liquidity concerns remains paramount. Stakeholders should watch how these developments unfold, particularly the effects of outstanding debts and active litigation on operational stability.